BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 32933390)

  • 1. [CME ECC 66: Torsade de Pointes: The Danger of a Rotating Heart Axis].
    Markendorf S; Saguner AM; Brunckhorst C
    Praxis (Bern 1994); 2020 Sep; 109(12):944-951. PubMed ID: 32933390
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [CME ECG 66/Answers: Torsade de Pointes: The Danger of a Rotating Heart Axis].
    Markendorf S; Saguner AM; Brunckhorst C
    Praxis (Bern 1994); 2020; 109(13):1035-1038. PubMed ID: 33050812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acquired prolongation of QT interval as a risk factor for torsade de pointes ventricular tachycardia: a narrative review for the anesthesiologist and intensivist.
    Uvelin A; Pejaković J; Mijatović V
    J Anesth; 2017 Jun; 31(3):413-423. PubMed ID: 28229241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pause-dependent torsade de pointes following acute myocardial infarction: a variant of the acquired long QT syndrome.
    Halkin A; Roth A; Lurie I; Fish R; Belhassen B; Viskin S
    J Am Coll Cardiol; 2001 Oct; 38(4):1168-74. PubMed ID: 11583899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [QT prolongation and torsade de pointes tachycardia during therapy with maprotiline. Differential diagnostic and therapeutic aspects].
    Lentini S; Rao ML; Schröder R; Lüderitz B; Bauriedel G
    Dtsch Med Wochenschr; 2001 Dec; 126(49):1396-400. PubMed ID: 11740632
    [TBL] [Abstract][Full Text] [Related]  

  • 6. QT interval prolongation and torsade de pointes.
    Patanè S; Marte F; Di Bella G
    Int J Cardiol; 2009 Jan; 131(2):e51-3. PubMed ID: 17689729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time- and rate-dependent alterations of the QT interval precede the onset of torsade de pointes in patients with acquired QT prolongation.
    Gilmour RF; Riccio ML; Locati EH; Maison-Blanche P; Coumel P; Schwartz PJ
    J Am Coll Cardiol; 1997 Jul; 30(1):209-17. PubMed ID: 9207644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epicardial activation patterns of torsade de pointes in canine hearts with quinidine-induced long QT interval but without myocardial infarction.
    Inoue H; Murakawa Y; Toda I; Nozaki A; Matsuo H; Mashima S; Sugimoto T
    Am Heart J; 1986 Jun; 111(6):1080-7. PubMed ID: 3716981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A practical approach to torsade de pointes.
    Roden DM
    Clin Cardiol; 1997 Mar; 20(3):285-90. PubMed ID: 9068917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Iatrogenic torsade de pointes induced by thioridazine].
    Paoloni P; Ciliberti D; Blasi N; Capone P
    Minerva Cardioangiol; 1992 Jun; 40(6):245-9. PubMed ID: 1407620
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Therapeutic hypothermia-induced QT prolongation and “torsade de pointes” ventricular tachycardia].
    Tomcsányi J; Arányi P; Arabadzisz H
    Orv Hetil; 2022 Mar; 163(13):523-526. PubMed ID: 35339994
    [TBL] [Abstract][Full Text] [Related]  

  • 12. QT interval prolongation, torsade de pointes and renal disease.
    Patanè S; Marte F; Di Bella G; Currò A; Coglitore S
    Int J Cardiol; 2008 Nov; 130(2):e71-3. PubMed ID: 18255176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Torsade de pointes induced by terfenadine in a patient with long QT syndrome.
    Koh KK; Rim MS; Yoon J; Kim SS
    J Electrocardiol; 1994 Oct; 27(4):343-6. PubMed ID: 7815014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care.
    Roden DM; Woosley RL; Primm RK
    Am Heart J; 1986 Jun; 111(6):1088-93. PubMed ID: 3716982
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluconazole-associated QT interval prolongation and Torsades de Pointes in a paediatric patient.
    Ünal Yüksekgönül A; Ertuğrul İ; Karagöz T
    Cardiol Young; 2021 Dec; 31(12):2035-2037. PubMed ID: 34024302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphic ventricular tachycardia, ischaemic ventricular fibrillation, and torsade de pointes: importance of the QT and the coupling interval in the differential diagnosis.
    Rosso R; Hochstadt A; Viskin D; Chorin E; Schwartz AL; Tovia-Brodie O; Laish-Farkash A; Havakuk O; Gepstein L; Banai S; Viskin S
    Eur Heart J; 2021 Oct; 42(38):3965-3975. PubMed ID: 33693589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
    Lu HR; Yan GX; Gallacher DJ
    J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Torsade de pointes: the clinical considerations.
    Gowda RM; Khan IA; Wilbur SL; Vasavada BC; Sacchi TJ
    Int J Cardiol; 2004 Jul; 96(1):1-6. PubMed ID: 15203254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Torsade de pointes induced by ajmaline.
    Haverkamp W; Mönnig G; Kirchhof P; Eckardt L; Borggrefe M; Breithardt G
    Z Kardiol; 2001 Aug; 90(8):586-90. PubMed ID: 11565214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arrhythmias in the congenital long QT syndrome: how often is torsade de pointes pause dependent?
    Viskin S; Fish R; Zeltser D; Belhassen B; Heller K; Brosh D; Laniado S; Barron HV
    Heart; 2000 Jun; 83(6):661-6. PubMed ID: 10814624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.